Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2005
12/15/2005WO2003027235A3 Afap sequences, polypeptides, antibodies and methods
12/15/2005WO2002083921A8 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
12/15/2005WO2002083855A3 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
12/15/2005US20050278796 FIAT nucleic acids and proteins and uses thereof
12/15/2005US20050277763 For cancer therapy
12/15/2005US20050277761 Potassium channel interactors polypeptides and uses thereof
12/15/2005US20050277616 Thymine nucleosides with anti-hepatitis B virus activity
12/15/2005US20050277613 Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases
12/15/2005US20050277611 Cationic cardiolipin analoges and its use thereof
12/15/2005US20050277606 Administering by direct injection into heart an expression vector comprising a nucleic acid sequence encoding AOP-1 operably linked to a promoter, wherein expression of nucleic acid sequence within cells of heart enhances production of AOP-1, protecting against myocardial cell death
12/15/2005US20050277603 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
12/15/2005US20050277597 Use of N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester to treat sunburn and other burns
12/15/2005US20050277596 Use of lacosamide; motor neuron disorders
12/15/2005US20050277595 Increasing hematopoietic cell survival to reduce side effects by administering a cytokine: colony stimulating factor, epidermal growth factor,, thrombopoietin, megakaryocyte development and growth factor, pixykines, stem cell factor, fms-like tyrosine kinase-ligand, or an interleukin
12/15/2005US20050277594 Polypeptide for the treatment of cancer and a method for preparation thereof
12/15/2005US20050277593 Therapeutic uses of Reg protein
12/15/2005US20050277592 Beta-peptides
12/15/2005US20050277591 Use of RPL41 to treat infections and inhibit cancer
12/15/2005US20050277590 Includes substitutions/modifications which enhance secretion/degradation resistance; drugs; for insulin release and controlling blood glucose concentration
12/15/2005US20050277589 Linear cationic peptides having antibacterial and/or antifungal properties
12/15/2005US20050277588 Low white blood cell titer
12/15/2005US20050277587 CD7 as biomarker and therapeutic target for psoriasis
12/15/2005US20050277585 Combinations of immunosupressive agents for the treatment or prevention of graft rejections
12/15/2005US20050277584 Pharmaceutical compositions comprising cyclosporins
12/15/2005US20050277583 Histone deacetylase inhibitors and process for producing the same
12/15/2005US20050277582 Method for inactivating gonadotrophs
12/15/2005US20050277581 prolonged serum half-life to permit treatment regimens of about once every 5-7 days or longer, while retaining antibacterial properties in vivo
12/15/2005US20050277579 Compositions for affecting weight loss
12/15/2005US20050277578 Immunity generation
12/15/2005US20050277577 Compositions and methods for treating diverticular disease
12/15/2005US20050277576 Fibroblast growth factors; endothelial growth factors; stem cells; gene therapy; creatine kinase
12/15/2005US20050277575 Therapeutic compositions and methods for treating diseases that involve angiogenesis
12/15/2005US20050277193 Vectors and methods for gene transfer
12/15/2005US20050277181 for increasing or decreasing binding of lysozyme polypeptide to Treponema pallidum P17 polypeptide (Tp17); immunoassay, ELISA
12/15/2005US20050277176 Human and mouse beta-defensins, antimicrobial peptides
12/15/2005US20050277165 Novel treatment
12/15/2005US20050277156 Useful as diagnostic markers for cardiac diseases and/or pathology
12/15/2005US20050277137 Diagnosing pancreatic cell proliferative disorders via concentration of tumor marker antigen in blood; immunoassay
12/15/2005US20050277123 Variants of NEDD4L associated with hypertension and viral budding
12/15/2005US20050277118 Methods for identifying subjects at risk of melanoma and treatments thereof
12/15/2005US20050277112 Novel therapeutic processes for treating infectious agents using same epitope specific antigens, and useful compositions therefor
12/15/2005US20050277106 Methods and active substances for protecting organs
12/15/2005US20050276871 Control of canine voluntary food intake
12/15/2005US20050276863 Methods for treatment of aneurysmal tissue
12/15/2005US20050276856 Non-aqueous single phase vehicles and formulations utilizing such vehicles
12/15/2005US20050276854 Bioimplant formulation
12/15/2005US20050276843 An aerosol drug delivery device containing PTH, cyclodextrin, and didecanoylphophatidylcholine that provides droplets of 25 to 700 microns in size; improved bioavailability; osteoporosis
12/15/2005US20050276821 Antigen protein and nucleic acid coding for said protein
12/15/2005US20050276820 structural modification alters the biological persistence, preferably the biological half-life
12/15/2005US20050276819 Helicobacter pylori CAI antigen
12/15/2005US20050276809 comprising antibodies that specifically bind caspase-8 as inhibitors; cancer; activation of the receptor-interacting protein (RIP, a serine-threonine kinase) and Jun N-terminal kinase induce cell death with the morphology of autophagy
12/15/2005US20050276808 Administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist, renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma
12/15/2005US20050276796 endowing a protein with bone-tissue targeting ability and improvement of its stability by means of addition of a short peptide consisting of acidic amino acids to the N-terminus of the protein; osteoporosis
12/15/2005US20050276795 Chemotherapeutic and prophylactic pharmaceutical compositions
12/15/2005US20050276787 Adeno-associated vector compositions for expression of factor VIII
12/15/2005US20050276786 Locally administering to tumor antigen-releasing agent, tumor leukocyte attractant and tumor interferon-gamma (IFN-g), and second type 1 inflammatory response-(IR1-)promoting agent for tumor therapy
12/15/2005US20050276785 Treatment of cardiomyopathy and of endothelial dysfunction
12/15/2005US20050276784 Ligand for the c-kit receptor and methods of use thereof
12/15/2005DE102004063927A1 Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden Use of low-dose erythropoietin for stimulation of endothelial progenitor cells and the organ regeneration and slowing progression of organ damage
12/15/2005DE102004025731A1 Antibakterielle Amid-Makrozyklen III Antibacterial amide macrocycles III
12/15/2005DE10158035B4 Cytostatisches Mittel und dessen Verwendung Cytostatic agent and its use
12/15/2005CA2580305A1 Polymer based nano-carriers for the solubilization and delivery of hydrophobic drugs
12/15/2005CA2572451A1 Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature
12/15/2005CA2569520A1 Egfr mutations
12/15/2005CA2569098A1 Combination therapy with glatiramer acetate and minocycline for the treatment of multiple sclerosis
12/15/2005CA2568781A1 Intrathymic administration of viral vectors for the induction of immune tolerance, the prevention or treatment of immunodeficiencies or autoimmune diseases
12/15/2005CA2568750A1 Compositions and methods for treatment of neovascular diseases
12/15/2005CA2568641A1 Sustained release composition
12/15/2005CA2568405A1 Biomarkers for monitoring inhibition of impdh pathway
12/15/2005CA2568218A1 Multiple agent therapy for sexual dysfunction
12/15/2005CA2568158A1 Treatment of amyotrophic lateral sclerosis
12/15/2005CA2567901A1 Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member
12/15/2005CA2567887A1 Method for screening and compositions for treating cancers
12/15/2005CA2567852A1 Treatment with cisplatin and an egfr-inhibitor
12/15/2005CA2567805A1 Tgf derepressors and uses related thereto
12/15/2005CA2567728A1 Griffithsin, glycosylation-resistant griffithsin, and related conjugates,compositions, nucleic acids, vectors,host cells, methods of production and methods of use
12/15/2005CA2567655A1 Binding moieties based on shark ignar domains
12/15/2005CA2567495A1 Methods for treating bleeding disorders using sulfated polysaccharides
12/15/2005CA2567491A1 Immune response assessment method
12/15/2005CA2567310A1 Stabilized interferon liquid formulations
12/15/2005CA2567309A1 Method of stabilizing proteins
12/15/2005CA2567030A1 Stable peptide mimetic of hiv gp41 fusion intermediate
12/15/2005CA2566974A1 Treatment with oxaliplatin and an egfr-inhibitor
12/15/2005CA2566864A1 Microbial biosurfactants comprising rhamnolipids as an agent for controlling pests
12/15/2005CA2566571A1 Treatment methods utilizing albumin-binding proteins as targets
12/15/2005CA2566506A1 Peptides for inducing a ctl and/or htl response to hepatitis c virus
12/15/2005CA2565827A1 Bispecific binding agents for modulating biological activity
12/15/2005CA2565801A1 Use of il-17 in the treatment of fertility-related disorders
12/15/2005CA2565524A1 Splice variant of unc5h2
12/15/2005CA2564092A1 Methods and compositions for the treatment of polycystic diseases
12/15/2005CA2563930A1 Method for activating of t cell protein tyrosine phosphatase and therapeutical methods based thereon
12/15/2005CA2563691A1 Cell death modulation via antagonists of fasl and fas activation
12/15/2005CA2562940A1 Methods of promoting cardiac cell proliferation
12/15/2005CA2562676A1 Use of gpcr54 ligands for the treatment of infertility
12/15/2005CA2558963A1 Omi pdz modulators
12/14/2005EP1605061A1 Neisseria genomic sequences and methods of their use
12/14/2005EP1605049A2 Fibrinolytically active polypeptide
12/14/2005EP1605046A1 Stably transfected cell lines expressing human GABA-A receptors with the subunit combination alpha-2, beta-3 and gamma-2
12/14/2005EP1605045A2 Polypeptides and nucleic acids encoding same
12/14/2005EP1604694A1 Composite device having osteoinductive and osteoconductive properties
1 ... 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 ... 3163